Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
| ▸ | BLM | P54132 | 1/20 | 0.44 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | NOS3 | P29474 | 1/20 | 0.33 |
| ▸ | NOS1 | P29475 | 1/20 | 0.33 |
| ▸ | NOS2 | P35228 | 1/20 | 0.33 |
| ▸ | DPP4 | P27487 | 1/20 | 0.33 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.33 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.33 |
| ▸ | SLC1A1 | P43005 | 2/20 | 0.32 |
| ▸ | GRM8 | O00222 | 1/20 | 0.32 |
| ▸ | GRM6 | O15303 | 1/20 | 0.32 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.32 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.32 |
| ▸ | GSR | P00390 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.32 |
| ▸ | GRM5 | P41594 | 1/20 | 0.32 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Valine SCHEMBL10428653 | 0.85 | ALOX15 (0.53) | ALOX15BLMPMP22KMT2ANOS3 | |
| SCHEMBL10382573 | 0.84 | ALOX15 (0.43) | ALOX15BLMPMP22KMT2ANOS3 | |
| Glutamine SCHEMBL10496120 | 0.84 | KMT2A (0.59) | ALOX15BLMPMP22KMT2ANOS3 | |
| SCHEMBL9716089 | 0.81 | ALOX15 (0.43) | ALOX15BLMPMP22KMT2ANOS3 | |
| SCHEMBL5082336 | 0.81 | ALOX15 (0.67) | ALOX15BLMPMP22KMT2ANOS3 | |
| SCHEMBL1537476 | 0.81 | ALOX15 (0.67) | ALOX15BLMPMP22KMT2ANOS3 | |
| Glutamine SCHEMBL14966642 | 0.81 | ALOX15 (0.38) | ALOX15BLMPMP22KMT2A | |
| Glutamine SCHEMBL9716071 | 0.80 | ALOX15 (0.40) | ALOX15BLMPMP22KMT2ASLC1A1 | |
| Lysine SCHEMBL2385063 | 0.80 | GSR (0.42) | ALOX15BLMPMP22KMT2ANOS3 | |
| Glutamine SCHEMBL7559917 | 0.79 | ALOX15 (0.70) | ALOX15BLMPMP22KMT2ANOS3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 424 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3498289-A1 | MONOMETHYLVALINE COMPOUNDS HAVING PHENYLALANINE SIDE-CHAIN MODIFICATIONS AT THE C-TERMINUS | Seattle Genetics, Inc. (US) | 2019-06-19 | — | — | EP | claimed |
| EP-2722051-B1 | Monomethylvaline compounds having phenylalanine side-chain modifications at the C-terminus | SEATTLE GENETICS INC (US) | 2018-11-07 | — | — | EP | claimed |
| EP-1917020-B1 | MONOMETHYLVALINE COMPOUNDS HAVING PHENYLALANINE SIDE-CHAIN MODIFICATIONS AT THE C-TERMINUS | SEATTLE GENETICS INC (US) | 2016-05-25 | — | — | EP | claimed |
| EP-2722051-A1 | Monomethylvaline compounds having phenylalanine side-chain modifications at the C-terminus | Seattle Genetics, Inc. (US) | 2014-04-23 | — | — | EP | claimed |
| US-8703714-B2 | Monomethylvaline compounds capable of conjugation to ligands | SEATTLE GENETICS, INC. (US) | 2014-04-22 | — | — | US | claimed |
| US-8512707-B2 | Methods of treating drug-resistant cancers | SEATTLE GENETICS, INC. (US) | 2013-08-20 | — | — | US | claimed |
| US-8343928-B2 | Monomethylvaline compounds having phenylalanine side-chain replacements at the C-terminus | SEATTLE GENETICS, INC. (US) | 2013-01-01 | — | — | US | claimed |
| US-20120003247-A1 | MONOMETHYLVALINE COMPOUNDS CAPABLE OF CONJUGATION TO LIGANDS | SEATTLE GENETICS, INC. (US) | 2012-01-05 | — | — | US | claimed |
| US-20100260786-A1 | METHODS OF TREATING DRUG-RESISTANT CANCERS | SEATTLE GENETICS, INC. (US) | 2010-10-14 | — | — | US | claimed |
| US-20090047296-A1 | Antibodies conjugated to Auristatin analogs via a maleimidocaproyl lingages; for treating cancer, autoimmune diseases and infectious diseases | SEATTLE GENETICS, INC. (US) | 2009-02-19 | — | — | US | claimed |
| US-20090018086-A1 | Monomethylvaline Compounds Having Phenylalanine Side-Chain Replacements at the C-Terminus | SEATTLE GENETICS, INC. (US) | 2009-01-15 | — | — | US | claimed |
| EP-1917020-A1 | MONOMETHYLVALINE COMPOUNDS HAVING PHENYLALANINE SIDE-CHAIN MODIFICATIONS AT THE C-TERMINUS | Seattle Genetics, Inc. (US) | 2008-05-07 | — | — | EP | claimed |
| WO-2007137170-A2 | ANTI-GLYPICAN-3 ANTIBODY DRUG CONJUGATES | SEATTLE GENETICS, INC. (US) | 2007-11-29 | — | — | WO | claimed |
| WO-2007103288-A2 | ENGINEERED ANTIBODY DRUG CONJUGATES | SEATTLE GENETICS, INC. (US) | 2007-09-13 | — | — | WO | claimed |
| CN-1938046-A | Monomethylvaline compounds capable of coupling to ligands | SEATTLE GENETICS INC (US) | 2007-03-28 | — | — | CN | claimed |
| WO-2007008848-A2 | MONOMETHYLVALINE COMPOUNDS HAVING PHENYLALANINE CARBOXY MODIFICATIONS AT THE C-TERMINUS | SEATTLE GENETICS, INC. (US) | 2007-01-18 | — | — | WO | claimed |
| WO-2007008603-A1 | MONOMETHYLVALINE COMPOUNDS HAVING PHENYLALANINE SIDE-CHAIN MODIFICATIONS AT THE C-TERMINUS | SEATTLE GENETICS, INC. (US) | 2007-01-18 | — | — | WO | claimed |
| EP-1725249-A2 | MONOMETHYLVALINE COMPOUNDS CAPABLE OF CONJUGATION TO LIGANDS | Seattle Genetics, Inc. (US) | 2006-11-29 | — | — | EP | claimed |
| US-20050238649-A1 | Auristatin and dolastatin analogs; for treating cancer, autoimmune diseases and infectious diseases | SEATTLE GENETICS, INC. (US) | 2005-10-27 | — | — | US | claimed |
| WO-2005081711-A2 | MONOMETHYLVALINE COMPOUNDS CAPABLE OF CONJUGATION TO LIGANDS | SEATTLE GENETICS, INC. (US) | 2005-09-09 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120003247-A1 | MONOMETHYLVALINE COMPOUNDS CAPABLE OF CONJUGATION TO LIGANDS | MMAB, CAD, VIM | ALOX15 3567/4885BLM 1527/4885PMP22 4443/4885 |
| US-20090047296-A1 | Antibodies conjugated to Auristatin analogs via a maleimidocaproyl lingages; for treating cancer, autoimmune diseases and infectious diseases | MMAB, CAD, TRIM59 | ALOX15 2501/4885BLM 2185/4885PMP22 2840/4885 |
| US-20100260786-A1 | METHODS OF TREATING DRUG-RESISTANT CANCERS | CD44, TP53, MKI67 | ALOX15 1946/4885BLM 677/4885PMP22 865/4885 |
| US-20050238649-A1 | Auristatin and dolastatin analogs; for treating cancer, autoimmune diseases and infectious diseases | CAD, MMAB, AURKC | ALOX15 2393/4885BLM 2686/4885PMP22 3109/4885 |
| US-20090018086-A1 | Monomethylvaline Compounds Having Phenylalanine Side-Chain Replacements at the C-Terminus | MMAB, DNPEP, MARCKS | ALOX15 4410/4885BLM 3002/4885PMP22 3884/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.